Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Butyrylthiocholine is a synthetic, sulfur-containing analog of butyrylcholine. Structurally, it consists of a trimethylammonium group attached to an ethyl chain linked to a butanoylthio group[8]. It is primarily used as a reagent in biochemical assays for the determination of butyrylcholinesterase activity, where it serves as an artificial substrate that is hydrolyzed by the enzyme to produce thiocholine and butyrate[1][2][3]. This property makes it valuable in research focused on cholinergic signaling pathways and in drug development targeting neurodegenerative diseases such as Alzheimer's disease[4]. Butyrylthiocholine itself does not have approved therapeutic indications and is not used clinically; its main application remains experimental and diagnostic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on butyrylthiocholine.